Pharmafile Logo

Lucid tackles Tough Mudder 2017

- PMLiVELast Saturday, twenty enthusiastic Lucidians took on the 2017 London South Tough Mudder Half challenge at the Holmbrush Estate in Surrey. Covering 5 miles and 13 imposing obstacles, the team tested their strength, endurance and teamwork – for charity. Prior to the event, they raised over £1800 for the charities Genetic Alliance UK and Bloodwise, in addition to supporting Tough Mudder’s official charity partner, Help for Heroes.

Lucid’s charity fundraising efforts were initiated by Team Marvel, who were soon joined in their mission by colleagues from across the Lucid Group. The brave participants assembled on the chilly Saturday morning, cheered on by their supporters in the crowd. “Faced with exorbitant enthusiasm by some and a little trepidation by others, we all supported each other through the race, and had a great time while we did,” said Ayala Donegan, Customer Experience Manager at Lucid.

Andrew Owen, Divisional Director and Lucid Charity Working Group leader, commented: “Collaboration to advance outcomes is at the heart of everything we do at Lucid, and our approach to charity is no different. Many people at Lucid have collectively chosen to participate in Tough Mudder because it’s a great way to support charities that share our vision, and is also an activity that’ll bring us together as a team, overcoming the pretty terrifying-looking obstacles and hopefully having fun on the way! I’m so proud that so many of us are taking part, that the entire company is supporting us, and that we can do something as a company collectively to support such worthwhile causes.”- PMLiVE

- PMLiVE

- PMLiVE

- PMLiVE

- PMLiVE

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

A summer meeting full of magical moments

In their day-to-day, everybody at Lucid Group strives to develop outstanding medical education programmes to improve patient outcomes. Over the summer, however, they like to take some time to turn...

Sir Henry presents Queen’s Award for Enterprise to Lucid Group

On 13 July, Lord Lieutenant Sir Henry presented Lucid Group with the Queen’s Award for Enterprise in International Trade. This award recognises UK-based businesses that have achieved outstanding growth overseas...

Lucid Group’s winning formula is recognised at Communiqué 2017

Lucid Group’s commitment to improving patient outcomes across the globe was recognised at the 2017 Communiqué Awards in London last night. The agency won the awards for Excellence in Communications...

Lucid Partners grows its medical writing team

The past year has been the most successful for Lucid Group yet. They have celebrated their 10th year of business, launched their new Strategic Consultancy, won a Queen’s Award for...

Using insights to effect behaviour change

The days when medical communication simply aimed to raise awareness of clinical challenges are well and truly over. In recent years, we have seen a clear shift towards changing physicians’...

All five of Lucid’s entries reach the shortlist for Communiqué 2017

Lucid Group is thrilled to learn that all its entries for the 2017 Communiqué Awards have been shortlisted as finalists! The categories include: Communications Consultancy of the Year Lucid Group   Excellence in Communications via...

Your career starts here

When working in medical communications, one of the most common questions we get asked is “What is it that you actually do?” Many students and graduates are unaware of medical...

Are you suffering from templatitis?

At times, it feels like procedures are designed to frustrate, and templates often hinder rather than help. Especially in strategic planning, where a certain degree of creativity and innovation is...

It’s time to shine for Lucid’s rare disease team

No team members were getting their hands dirty today! Instead, they were treated to car valets and manicures as a thank you for all their hard work delivering a number...

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.